KR20160085231A - Propionibacterium Acnes Antimicrobial and Cosmetics Therewith - Google Patents
Propionibacterium Acnes Antimicrobial and Cosmetics Therewith Download PDFInfo
- Publication number
- KR20160085231A KR20160085231A KR1020160080139A KR20160080139A KR20160085231A KR 20160085231 A KR20160085231 A KR 20160085231A KR 1020160080139 A KR1020160080139 A KR 1020160080139A KR 20160080139 A KR20160080139 A KR 20160080139A KR 20160085231 A KR20160085231 A KR 20160085231A
- Authority
- KR
- South Korea
- Prior art keywords
- acne
- powder
- skin
- extract
- ethanol
- Prior art date
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 18
- 241000186427 Cutibacterium acnes Species 0.000 title description 15
- 229940055019 propionibacterium acne Drugs 0.000 title description 2
- 230000000845 anti-microbial effect Effects 0.000 title 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 87
- 206010000496 acne Diseases 0.000 claims abstract description 87
- 239000000843 powder Substances 0.000 claims abstract description 39
- 239000004599 antimicrobial Substances 0.000 claims abstract description 26
- 244000061458 Solanum melongena Species 0.000 claims abstract description 16
- 235000002597 Solanum melongena Nutrition 0.000 claims abstract description 16
- 241000219745 Lupinus Species 0.000 claims description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 239000000469 ethanolic extract Substances 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 11
- 238000002481 ethanol extraction Methods 0.000 claims description 2
- 241001400033 Omia Species 0.000 claims 1
- 210000001732 sebaceous gland Anatomy 0.000 abstract description 22
- 210000003780 hair follicle Anatomy 0.000 abstract description 13
- 230000003071 parasitic effect Effects 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 206010040880 Skin irritation Diseases 0.000 abstract description 5
- 230000036556 skin irritation Effects 0.000 abstract description 5
- 231100000475 skin irritation Toxicity 0.000 abstract description 5
- 208000010201 Exanthema Diseases 0.000 abstract description 4
- 201000005884 exanthem Diseases 0.000 abstract description 4
- 206010037844 rash Diseases 0.000 abstract description 4
- 208000017520 skin disease Diseases 0.000 abstract description 4
- 231100000046 skin rash Toxicity 0.000 abstract description 3
- 230000002411 adverse Effects 0.000 abstract 1
- 239000000284 extract Substances 0.000 description 37
- 239000000243 solution Substances 0.000 description 25
- 210000003491 skin Anatomy 0.000 description 24
- 241000894006 Bacteria Species 0.000 description 23
- 239000011148 porous material Substances 0.000 description 15
- 210000002510 keratinocyte Anatomy 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 12
- 206010061218 Inflammation Diseases 0.000 description 11
- 210000002374 sebum Anatomy 0.000 description 11
- 230000004054 inflammatory process Effects 0.000 description 9
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 9
- 230000003902 lesion Effects 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 238000010298 pulverizing process Methods 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 6
- 206010014970 Ephelides Diseases 0.000 description 5
- 208000003351 Melanosis Diseases 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004207 dermis Anatomy 0.000 description 5
- 230000003325 follicular Effects 0.000 description 5
- 210000004209 hair Anatomy 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 230000003780 keratinization Effects 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 206010012438 Dermatitis atopic Diseases 0.000 description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 4
- 208000012641 Pigmentation disease Diseases 0.000 description 4
- 206010037888 Rash pustular Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000003255 anti-acne Effects 0.000 description 4
- 201000008937 atopic dermatitis Diseases 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 235000020778 linoleic acid Nutrition 0.000 description 4
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 208000029561 pustule Diseases 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 102000004890 Interleukin-8 Human genes 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 241001400472 Omiza Species 0.000 description 3
- 206010033733 Papule Diseases 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000003399 chemotactic effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 235000013345 egg yolk Nutrition 0.000 description 3
- 210000002969 egg yolk Anatomy 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 210000004761 scalp Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QYIMSPSDBYKPPY-BANQPHDMSA-N 2,3-epoxysqualene Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C=C(/C)CC\C=C(/C)CCC1OC1(C)C QYIMSPSDBYKPPY-BANQPHDMSA-N 0.000 description 2
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 241001128004 Demodex Species 0.000 description 2
- 241001218273 Demodex brevis Species 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- -1 IL-1α Proteins 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000721454 Pemphigus Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- MQYXUWHLBZFQQO-QGTGJCAVSA-N lupeol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C MQYXUWHLBZFQQO-QGTGJCAVSA-N 0.000 description 2
- PKGKOZOYXQMJNG-UHFFFAOYSA-N lupeol Natural products CC(=C)C1CC2C(C)(CCC3C4(C)CCC5C(C)(C)C(O)CCC5(C)C4CCC23C)C1 PKGKOZOYXQMJNG-UHFFFAOYSA-N 0.000 description 2
- 230000024241 parasitism Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- 108010048623 Collagen Receptors Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000009774 Follicular Cyst Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100032817 Integrin alpha-5 Human genes 0.000 description 1
- 102000000507 Integrin alpha2 Human genes 0.000 description 1
- 102000000510 Integrin alpha3 Human genes 0.000 description 1
- 108010041357 Integrin alpha3 Proteins 0.000 description 1
- 108010041014 Integrin alpha5 Proteins 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 206010023204 Joint dislocation Diseases 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 108010040897 Microfilament Proteins Proteins 0.000 description 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 210000001096 cystic duct Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-M leukotriene B4(1-) Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC([O-])=O VNYSSYRCGWBHLG-AMOLWHMGSA-M 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008529 pathological progression Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 모낭 안이나 피지선 내에 기생하면서, 피부질환을 일으키고 여드름을 야기하는 여드름균을 피부자극이나 발진 등 부작용 없이 사멸할 수 있는 여드름균 항균제 및 그것을 함유한 화장품에 관한 것으로, 가지 분말(Solanum melongena L)의 에탄올추출물을 포함하는 것을 특징으로 한다.The present invention relates to an antimicrobial agent for acne, which is parasitic in a hair follicle or sebaceous gland and which can cause skin diseases and cause acne to disappear without adverse effects such as skin irritation or rash, and cosmetics containing the same, wherein a branching powder (Solanum melongena L). ≪ / RTI >
Description
본 발명은 가지(Solanum melongena L)분말의 에탄올추출물로 이루어진 여드름균 항균제 및 그것을 함유한 화장품에 관한 것으로, 더 상세하게는 모낭 안이나 피지선 내에 기생하면서, 피부질환을 일으키고 여드름을 야기하는 여드름균을 피부자극이나 발진 등 부작용 없이 사멸할 수 있는 가지(Solanum melongena L)분말의 에탄올추출물 및 이 추출물을 함유하여 여드름을 예방하고 여드름 부위 색소 침착을 감소할 수 있는 화장품에 관한 것이다.
The present invention relates to an antimicrobial agent for acne, comprising an ethanol extract of Solanum melongena L powder, and a cosmetic containing the same. More particularly, the present invention relates to an antimicrobial agent for acne, which causes skin diseases and causes acne in a hair follicle or sebaceous glands The present invention relates to an ethanol extract of Solanum melongena L powder which can be killed without side effects such as skin irritation or rash and a cosmetic product containing this extract and capable of preventing acne and reducing pigmentation of acne spot.
경제가 발전하고 생활수준이 향상되면서 아름다움에 대한 욕구가 커져가는 현실에서 피부의 아름다움을 추구하는 것은 자연스런 현상이 되었으며 이에 따라 피부을 아름답게 하는 연구가 여러 분야에서 활발하게 진행되고 있다. 최근 들어 피부에 영향을 미치는 여러 가지 요인들 중 여드름균에 대한 연구가 활발하게 이루어지고 있다.
As the economy develops and the level of living improves, the desire for beauty grows. In pursuit of beauty of the skin, it has become a natural phenomenon, and studies that make skin beautiful have been actively conducted in various fields. Recently, acne bacterium has been actively studied among various factors affecting the skin.
여드름은 청년 및 성인 대부분이 겪는 모피지선낭의 만성적 염증 질환이다. 본 병리는 위치 및 중증도에 따라 다르다. 청년들의 여드름은 85% 경우 중등도 또는 가벼운 증상이다. 중증 여드름의15% 중, 3% 내지 4%의 남성 및 0.4%의 여성은 결절성 및 만성 여드름을 가진다. 다양한 위치들에서 공통적인 요소는 피지 잔류이며, 이는 임상적으로 특정한 기본 병소들로 나타난다.
Acne is a chronic inflammatory disease of the follicular pouch that affects most young adults and adults. This pathology varies according to location and severity. Young acne is moderate or mild in 85% of cases. Among 15% of severe acne, 3% to 4% of men and 0.4% of women have nodular and chronic acne. A common element in various locations is sebum residues, which appear clinically as specific basal lesions.
본 병리는 여러 진행 단계들에서 팽창된 모피지선낭에 해당되는 정체성 병소들, 표면 염증성 병소 (구진 및 농포), 또는 깊은 염증성 병소 (결절)로 나타나고, 이들 This pathology may be manifested by the presence of an identity lesion, a surface inflammatory lesion (pustule and pustule), or a deep inflammatory lesion (nodule) that corresponds to the enlarged folliculocyst in various stages of progression,
여드름 병소는 영구적 위축성 흉터, 비대 흉터, 또는 일반적으로 일과성 및/또는 색소침작 홍반성 반점을 남긴다. Acne lesions leave permanent atrophic scars, hypertrophic scars, or, in general, transient and / or pigmented irritation spots.
여드름은 모피지선낭 (짧은 털을 가지는 매우 특이한 주머니) 질환이고 매우 밀접하게 연관되고 과지루, 과각질, 여드름 유발균 (Propionibacterium acnes) (P. acnes) 증식 및 염증이라는 연속적인 4개의 인자들이 관여된다.
Acne is a follicular disease (a very specific pouch with short hair) and is closely related and involves four sequential factors: hyperplasia, hyperkeratosis, Propionibacterium acnes (P. acnes) proliferation and inflammation do.
과지루화 (피지 과다분비)는 여드름의 초기 인자이다. 이것은 호르몬 특히 안드로겐-의존적이다. 실제로, 피지 분비는 유리 테스토스테론에서 5-α-환원효소 타입 1에 의해 피지 세포들에서 생성되는 디히드로테스토스테론 (DHT)에 의해 촉진되고 유지된다. 여드름에서, 순환 안드로겐이 정상 수준으로 존재하고 부분적으로 국부적 5-α-환원효소 과다활동으로 인하여 안드로겐에 대한 피지샘의 특이한 민감성으로 병리가 유발된다.
And boring (sebaceous glands) are the earliest factors of acne. This is hormone-specific and androgen-dependent. Indeed, sebaceous glands are promoted and maintained by dihydrotestosterone (DHT) produced in sebaceous cells by 5-alpha-reductase type 1 in free testosterone. In acne, pathogens are caused by the specific sensitivity of sebaceous glands to androgens due to circulating androgens present at normal levels and partially localized 5-alpha-reductase overactivity.
피지는 스쿠알렌 (12%), 왁스 (26%), 콜레스테롤, 콜레스테롤 에스테르 및 트리글리세리드의 혼합물로 이루어진다. 여드름 피부의 피지는 P. acnes에 의해 분비된 리파아제의 트리글리세리드 가수분해에 따라 여드름 없는 개체와 비교하여 더 높은 농도의 지방산 및 스쿠알렌 산화물 (염증-촉진)을 가진다. 동시에, 바로 아래 표피 표면과 비교할 때 면포에서 리놀레산 (항-염증성)이 결핍된다.
The sebum consists of a mixture of squalene (12%), wax (26%), cholesterol, cholesterol esters and triglycerides. The sebum of acne skin has a higher concentration of fatty acid and squalene oxide (inflammation-promoting) compared to individuals without acne, due to the triglyceride hydrolysis of lipase secreted by P. acnes. At the same time, linoleic acid (anti-inflammatory) is deficient in cottonseed when compared to the immediate surface of the skin.
이러한 염증-촉진 및 항-염증 지질 사이 균형 역전은 여드름 발병 원인이고, 즉 면포 형성에 이르는 난포상피 각질화 장애 원인이다. 한편, 과산화 스쿠알렌은 염증의 지질 전달물질 (류코트리엔 B4 및 프로스타글란딘 E2을 증가) 및 IL-6 생성을 활성화시킨다. 다른 한편으로, 리놀레산 감소로 과각질화를 유발하고 표피를 더욱 투과 및 더욱 취약하게 하여, 미생물 성장 및 시토카인 (특히 인터류킨-1α) 및 염증을 유도하는 화학주성 물질들 생성을 촉진한다.
This reversal of inflammation-promoting and anti-inflammatory lipid balance is the cause of acne, which is the cause of ovarian epithelial keratinization disorders leading to cotton formation. On the other hand, squalene peroxide activates inflammatory lipid transporters (increasing leukotriene B4 and prostaglandin E2) and IL-6 production. On the other hand, the reduction of linoleic acid leads to keratinization and makes the epidermis more permeable and more vulnerable, promoting microbial growth and the production of cytokines (especially interleukin-1 alpha) and chemotactic substances that lead to inflammation.
과각질화는 모피지선낭 내벽을 따르는 세포들 (각질세포)의 이상 증식이다. 각질세포는 매우 신속하게 박리되어 미세면포 형성을 유도한다. 하위누두에서 모피지선낭 관 폐쇄가 일어난다. 이것은 서로 분리되지 않고 관을 막아버리는 각질세포의 증식, 유착 및 분화 이상에 의한 것이다. 정상 상태에서는, 각질세포가 분리되고, 이에 따라 피지는 공극을 자유로이 통과한다. 과각질화 경우에는, 각질세포는 서로 부착되어, 피지 방출이 방해된다. 따라서, 피지가 과다 분비될 뿐 아니라 끝이 막인 좁은 공극에 의해 방출이 제한된다. 피지 흐름이 모피지선낭 내부에서 갇혀 세포 조직 파편들은 미세낭 또는 폐쇄 면포라고 불리는 단단하고 약간 흰색의 피지 마개를 형성한다.
And keratinization are abnormal proliferation of cells (keratinocytes) along the inner wall of the follicular pouch. The keratinocytes are very rapidly dissociated to induce microfacial formation. Follicular branch occlusion occurs in the subluxation area. This is due to abnormal growth, adhesion and differentiation of keratinocytes, which are not separated from each other and block the tube. In normal conditions, the keratinocytes are separated, and the sebum passes freely through the cavity. And in the case of keratinization, keratinocytes adhere to each other, and sebum release is disturbed. Therefore, not only is sebum excess secreted, but also the emission is limited by the narrow pores with the end cap. The sebaceous flow is trapped inside the follicle pouch and cellular tissue debris forms a hard, slightly white sebaceous plug called a microcyst or a closed skin.
각질세포 과다증식단계에서, 여드름이 있는 개체의 모피지선낭 관의 각질세포는 건강한 대조 개체와 비교하여 더 높은 증식 지수 (Ki-67 표지)를 가진다. 이러한 증식 지수 증가는 병소 영역 및 외견상 건강한 여드름 영역에서 발견된다. 이것은 특히 미세면포 특징(과다증식 및 이상 분화) 원인인 IL-1α 생성과 관련된다.
In the keratinocyte hyperplasia stage, keratinocytes of follicular cysts of individuals with acne have a higher proliferation index (Ki-67 label) as compared to healthy controls. This increase in proliferation index is found in the lesion area and the apparently healthy acne area. This is particularly associated with the production of IL-l [alpha], the cause of micro-facial features (hyperproliferation and aberrant differentiation).
유착 (adhesion) 분자로서 인테그린은 각질세포들 사이 응집을 가능하게 하는 유착 분자이다. 이것은 특히 각질세포 증식 및 이동을 조절한다. 여드름에서, 여드름 낭들의 각질세포 하부누두에 의한 인테그린 α2, α3 및 α5 발현 변경이 있다. 이러한 변경 역시 미세면포 형성에 기여한다.
As an adhesion molecule, integrin is an adhesion molecule that enables aggregation between keratinocytes. This specifically regulates keratinocyte proliferation and migration. In acne, there is a change in integrin alpha 2, alpha 3 and alpha 5 expression by the lower keratinocytes of the acinar cells. These changes also contribute to microfacial formation.
피지 조성과정에서 과지루화는 희석에 의해 피지의 리놀레산 농도를 감소시킨다. 이러한 리놀레산 부족 및 유리 지방산 증가는, 각질세포 하부누두 분화를 비정상적으로 유도하고 이 역시 미세면포 형성에 기여하고 염증을 촉발시킨다.
In the process of forming sebum, hyperphosphorylation reduces the concentration of linoleic acid in sebum by dilution. Such an increase in linoleic acid deficiency and free fatty acid abnormally induces keratinocyte lower nodule differentiation, which also contributes to the formation of microfilament and triggers inflammation.
염증 현상은 병리 진행, 특히 염증성 병소 형성뿐 아니라 흉터 출현에 원인이 되므로, 여드름에서 기본적인 역할을 한다.
Inflammation plays a fundamental role in acne because it causes pathological progression, especially inflammatory lesions as well as scarring.
이러한 염증 과정은 다중 인자적이고 직간접적으로 P. acnes 증식의 결과이다. P.acnes는 표피 균주의 공생균이다. 정상 피부에서, P. acnes는 모피지선낭 기저에서 발달하여 피지를 통하여 표피 표면에 이른다. 여드름에서, 각질세포의 이상 축적 및 낭포 관에서의 과잉 피지로 인하여 P. acnes 증식의 이상 환경이 조성되어 병리 과정에서 염증 반응을 일으킨다. P.acnes 는 다양한 화학주성 인자들, 염증-촉진 분자들 및 프로테아제를 생성하며 이들은 여드름의 염증 반응의 원인이 된다.
These inflammatory processes are the result of multiple and direct or indirect P. acnes proliferation. P. acnes is a symbiotic of the epidermis. In normal skin, P. acnes develops from the base of the follicle and reaches the surface of the epidermis through sebum. In acne, abnormal accumulation of keratinocytes and excessive sebum in cystic ducts cause an abnormal environment of P. acnes proliferation and cause an inflammatory reaction during pathology. P. acnes produces a variety of chemotactic factors, inflammation-promoting molecules and proteases that cause acne inflammation.
한편, P.acnes 에 의해 생성되는 리파아제는 피지 트리글리세리드를 유리 지방산으로 가수분해하고 이들은 화학주성 물질들을 자극하여 과립백혈구를 향하여 방출시킨다. 이들 중성구 과립백혈구는 모낭 주위 조직에 리소솜성 효소를 방출하고 이는 모피지선낭 벽을 파열하여 염증을 완전히 확산시킨다. 다른 한편으로, P.acnes 는 톨(Toll)-유사 수용체 (TLR2 및 TLR4)를 통하여 면역 세포들에서 즉각 면역을 사용하여 염증성 시토카인 (IL-1α, TNFα, IL-6, IL-8, TGFα) 방출로 세포의 급격한 활성을 유도한다. 각질세포 또한 P.acnes 자극 후 시토카인, 특히 IL-1α, TNFα 및 케모카인 IL- 8 분비에 직접 관여된다. IL-8 생성 증가는 낭포의 과각질화와 연관되고 염증성 세포들이 모피지선낭을 향하여 돌진하는 원인이 된다(화학주성 효과). P.acnes 에 의한 TLR 및 전사인자 NFκB 활성은 또한 MMP (특히 MMP-1, MMP-2, MMP-3 및 MMP-9) 방출을 유도한다. 이들 프로테아제는 모피지선낭 주위에 있는 결합조직섬유를 공격하고 팽창된 낭포 벽 연화 및 파열뿐 아니라 진피에서 염증 확산에 관여한다. 이들 역시 흉터 형성의 원인이 된다.
On the other hand, lipases produced by P. acnes hydrolyze sebum triglycerides into free fatty acids, which stimulate chemotactic substances and release them towards granulocytes. These neutrophil granulocytes emit a rysosomal enzyme in the surrounding tissue of the hair follicle, which ruptures the folliculocyte wall and completely diffuses the inflammation. On the other hand, P. acnes has been shown to induce inflammatory cytokines (IL-1α, TNFα, IL-6, IL-8, TGFα) using immediate immune responses in immune cells via Toll-like receptors (TLR2 and TLR4) Release induces the abrupt activity of the cells. The keratinocytes are also directly involved in the secretion of cytokines, particularly IL-1α, TNFα and chemokine IL-8, after P. acnes stimulation. Increased production of IL-8 is associated with hyperkeratosis of the cysts and causes inflammatory cells to rush toward the follicular parenchyma (chemotactic effect). TLRs and transcription factors by P. acnes NFκB activity also induces MMP (especially MMP-1, MMP-2, MMP-3 and MMP-9) release. These proteases attack connective tissue fibers around the folliculi cage and are involved in inflammation spreading from the dermis as well as softening and rupturing of the expanded cyst wall. These also cause scar formation.
또한, 흉터로 진전되기 쉬운 여드름 환자들에서, 염증성 반응은 높은 혈관생성으로 더욱 심하게 지속된다. 이러한 측면에서, 혈관내피성장인자 (VEGF)는 피부를 자극하는 혈관 투과율을 증가시키고, 염증성/내피세포들을 유인하고 혈관생성을 촉진시켜 이들 병소 촉진에 능동적 기능을 한다. P.acnes는 항원-제시 세포들 간섭 없이 수용체에 직접 결합하여 T 림프구를 직접 활성화시키는 초항원으로 작용하여, 작동세포들을 더욱 신속하고 더욱 효과적으로 활성화시킨다. 따라서 염증 반응이 증폭된다. 궁극적으로, 연장된 염증 반응은 구진, 농포 및 결절이 출현되는데 중요한 원인이 된다.
In addition, in acne patients who are susceptible to developing scarring, the inflammatory response continues to be more severe with high blood vessel production. In this respect, vascular endothelial growth factor (VEGF) increases vascular permeability to stimulate the skin, induces inflammatory / endothelial cells and promotes angiogenesis to actively promote these lesions. P. acnes acts as a superantigen that directly binds to receptors and directly activates T lymphocytes without interfering with antigen-presenting cells, thus activating the working cells more rapidly and more effectively. Thus, the inflammatory response is amplified. Ultimately, the prolonged inflammatory response is an important cause of the appearance of papules, pustules and nodules.
P.acnes로 Demodex folicurum과 Demodex brevis라는 여드름균이 알려져 있다. Demodex folicurum은 주로 모낭 안에서 기생하며 몸체가 비교적 길고, Demodex brevis는 주로 얕은 피지선내에서 기생하며 몸체가 비교적 짧다. 성인의 눈꺼풀이나 코 주위, 외이도(外耳道), 머리 등의 피지선(皮脂腺)과 모낭에서 90%이상의 확률로 발견되는 여드름균은 반투명한 유백색을 띄고 있으며, 암수가 따로 존재하고 평균길이는 0.28mm이고 굵기는 사람머리카락의 1/2-2/3정도이다. 계단형 머리와 양쪽에 4개씩 8개의 거칠고 짧은 다리를 가지고 있고 긴 꼬리를 갖고 있다. 여드름균의 형태는 각기 서로 다른 특징이 있어서 사람과 동물사이 또는 각각 다른 동물사이에는 전염되지 않지만 사람끼리 또는 같은 동물끼리 피부를 접촉하면 전염되고 계속적으로 기생하게 된다. 여드름균의 생활은 중간숙주 없이 모낭과 피지선내에서 기생하면서 모든 성장이 진행되고, 암수가 구분되어 생식시 대부분 모낭 밖 피부에서 교미한 후 근처 모낭이나 피지선내에 들어가 알을 낳고 번식한다. 암컷은 배 앞쪽에 생식문이 열려 있고, 수컷은 둘째 및 셋째 걷는 다리 사이에 두 갈래로 갈라진 생식기가 있다. 번식력이 아주 강하여 암수가 교미 후 12시간이 지나면 50-60개의 알을 낳고 2주에는 성충이 되며 성충이 된 후 30-60일간 피부 속에 살다가 죽는다. 모낭이나 피지선내에서 집게발로 조직세포를 찔러서 영양분을 흡수하여 성장발육하며 이러한 모든 과정이 모낭과 피지선내에서 이뤄지면서 여드름균의 분비배설물, 사망 잔해 등이 쌓여서 모공과 피지선을 오염시키고 피부호흡을 방해한다. 빛을 싫어하고 따뜻한 것을 좋아하는 여드름균은 사람이 잠든 밤에 주로 활동하며 이때 성충은 모낭에서 나와 암수가 교미한다. 연령이 높을수록 여드름균의 기생비율이 높고, 지성두피에서 많이 발견되며, 모발의 세정주기가 짧을수록 기생비율이 낮고 성병 및 가족력에는 유의성을 보이지 않는다.P. acnes is known as an acne bacterium called Demodex foliumurum and Demodex brevis. Demodex folicurum is mainly parasitic in the hair follicle, the body is relatively long, Demodex brevis is mainly parasitic in the shallow sebaceous glands, and the body is relatively short. The acne bacteria found in the sebaceous glands and sebaceous glands of the adult eyelids, nose, ear canal, and hair follicles are found to have translucent milky white color, and male and female are separately present and mean length is 0.28 mm The thickness is about 1 / 2-2 / 3 of human hair. It has a stepped head and eight coarse short legs, four on each side, and has a long tail. The shape of the acne bacterium has different characteristics, so it does not spread between human beings or between different animals, but when they come into contact with each other or between the same animals, they become infected and become parasitic continuously. The life of acne bacterium is parasitic in hair follicles and sebaceous glands without intermediate hosts, and all the growth is progressed. The male and female parts are separated and mostly mate at the skin outside the hair follicle and enter the nearby hair follicles or sebaceous glands. The female has a reproductive door in front of the abdomen, and the male has a bifurcated genital between the second and third legs. Reproductive power is very strong, so that male and female breeds 50-60 eggs after 12 hours of mating, becomes an adult in 2 weeks, and lives in the skin for 30-60 days after becoming an adult. In the hair follicles and sebaceous glands, the tissue cells are pierced with nippers to absorb the nutrients and grow and develop. All of these processes are carried out in the hair follicles and sebaceous glands, and secretion feces and debris from the acne bacteria accumulate to pollute the pores and sebaceous glands. do. Acne fungus, which hates light and loves warm, is mainly active at night when a person is asleep. The higher the age, the higher the parasitism rate of acne, and the more frequent the hair cleansing cycle, the lower the parasitism rate and the less the sex and the family history.
여드름균에 관한 간행물은 여드름균이 피부에 미치는 영향을 중심으로 수백 편이 발표되고 있으며, 여드름균에 대한 연구가 진행되면서 여드름균이 모발과 피부에서 기생하면서 여드름 뿐 아니라 여드름, 기미, 주근깨, 반점, 모공의 확대 등을 일으키는데 상승 작용을 한다고 밝혀지고 있다.
As a result of studies on acne bacteria, acne bacteria are parasitized on hair and skin, and not only acne but also acne, spots, freckles, spots, And enlargement of the pores.
지금까지 연구된 여러 논문들을 정리하면 여드름균은 다음과 같이, 여드름, 기미, 주근깨, 피부반점, 모공의 확대, 가려움증, 여드름, 피부노화, 아토피성피부염, 기타 여러 가지 피부의 염증 등을 악화시키는 것으로 알려져 있다.
To summarize several papers that have been studied so far, acne bacteria can cause acne, spots, freckles, skin spots, enlargement of pores, itching, acne, skin aging, atopic dermatitis and various other skin irritations .
첫째, 여드름균이 피지선을 이동할 때, 모공 속을 출입할 때, 피부 위를 기어 다닐 때 피부는 가려움증을 느끼게 된다. 여드름균의 분비물과 배설물, 죽은 세포와 그 잔해들이 물리화학적 반응을 일으켜서 심각한 피부질환과 각화현상을 일으킨다. 여드름균은 진피층에 기생하며 진피층의 콜라겐과 엘라스틴을 갉아먹으며 진피층에 얽혀 있는 실핏줄을 파괴하여 피부의 자생력을 악화시킨다.
First, when the acne bacterium moves on the sebaceous glands, enters and exits the pore, and crawls over the skin, the skin feels itchy. Acne secretions, feces, dead cells and their wastes cause physiochemical reactions that cause serious skin diseases and keratinization. Acne bacteria are parasitic on the dermis layer and eat collagen and elastin of the dermis layer and destroy the vascular cord entangled in the dermis layer and deteriorate the self-vitality of the skin.
둘째, 피부에 사용하는 각종 화장품들 속에 들어있는 많은 영양분들이 피부 속으로 흡수되기 전에 오히려 수많은 여드름균의 영양분으로 사용되어 피부의 영양공급을 억제한다.
Second, many nutrients contained in various cosmetics used for skin are used as nutrients of many acne bacteria before they are absorbed into the skin, thereby suppressing nutrition of the skin.
셋째, 머리카락 굵기의 1/2-2/3 정도 되는 여드름균들이 한 개의 모공 속에 7-8마리가 우글거리며 수없이 모공을 출입하게 되면 모공은 늘어나게 되고 피부는 처짐과 동시에 주름이 늘어나고 피부에 탄력이 없어지게 된다.
Third, when acne bacteria of about 1 / 2-2 / 3 of the thickness of hair are piled up in the pores of one to seven or eight, the pores are stretched out, the skin is stretched and the wrinkles are increased at the same time as the skin is slackened. .
넷째, 여드름균은 피부에 색소침착의 원인으로 작용한다. 기미, 주근깨, 검버섯 등의 색소침착은 모공 속에 각종 오염물질이나 화장품 찌꺼기와 수명을 다한 여드름균의 잔해물들이 모공 속에서 썩고 부패하면 피부를 자극하여 멜라닌 색소의 분비를 촉진하고, 진피층에서 색소분해를 방해하여 일어나는 현상이다.
Fourth, acne bacterium causes skin pigmentation. Pigmentation such as spots, freckles, and black spots is caused by various contaminants in the pores, cosmetic residue, and debris from the acne bacterium that have reached the end of its life spoil and rot in the pores, stimulating the skin to promote the secretion of melanin pigment, This is a phenomenon caused by interference.
다섯째, 여드름균은 피지선에 기생하며 진피 층의 주요성분인 콜라겐과 엘라스틴을 갉아먹고 세포조직과 모세혈관을 파괴시켜 피부의 조기노화를 촉진한다.
Fifth, acne bacteria are parasitic on sebaceous glands and digest collagen and elastin, which are the main components of dermis layer, and destroy cellular tissues and capillaries to promote premature aging of skin.
여섯째, 성인 아토피성 피부염환자의 알레르기 반응원인을 찾기 위해 패치테스트를 한 결과 50% 이상이 진드기 류에 양성반응을 나타내기도 한다.
Sixth, patch test was conducted to find the cause of allergic reaction in adults with atopic dermatitis.
일곱째, 여드름균은 모공을 출입하면서 모공을 넓게 하고, 모근에 염증을 일으켜 여드름의 원인이 된다.
Seventh, Acne bacterium spreads pores through the pores, worsens the hair follicle, causing acne.
여드름 치료 방법으로는 초기 경증의 여드름이나 면포만 있는 경우에는 면포 용해제인 retinoids 등을 국소 도포 방법으로 치료하며 면포와 구진, 농포가 혼합된 경증에서는 국소도포 항생제와 병용하여 치료하고, 치료에 잘 반응하지 않는 여드름이나 심한 응괴성 여드름에는 전신요법으로 isotretinoin을 경구 투여하는 방법 등이 알려져 있다.
The acne treatment method is to treat the acne with only mild acne or cottonseed, and the retinoids such as retinoids are treated with topical application method. In case of mixed mucosa with papules, papules and pustules, they are treated with topical antibiotics, It has been known that oral treatment with isotretinoin for systemic acne or severe acne without acne.
그러나, 이러한 치료 방법들은 피부 자극을 야기하거나, 기형 유발 등 부작용이 따르는 문제점이 있다.
However, such treatment methods have problems in that they cause skin irritation and side effects such as malformation.
상술한 종래 생약제 추출물을 주재료로 하는 여드름균 항균제의 문제점을 해결하고자 안출된 본 발명은 피부 자극 없이 여드름균에 대한 사멸효과를 갖는 천연물 추출 여드름균 항균제 및 그것을 함유한 화장품을 제공하는 데 그 목적이 있다.
It is an object of the present invention to solve the problems of the conventional antimicrobial agent using the conventional herbal medicine extract as a main ingredient and to provide a natural product-extracting acne antimicrobial agent having a killing effect against acne bacteria without skin irritation and cosmetics containing the same. have.
본 발명의 다른 목적은 사람의 두피 뿐만아니라 몸 전체에 분포하는 모공이나 피지선에 서식하여 국소적인 병변 뿐 아니라 전신적인 피부병변을 야기하는 여드름균에 적용하여 피부질환(천포창, 건선, 아토피성 피부염 등), 여드름, 기미, 주근깨, 반점, 모공의 확대 등을 치료할 수 있는 여드름균 항균제를 제공하는 데 있다.
Another object of the present invention is to provide a method for treating skin diseases (pemphigus, psoriasis, atopic dermatitis, etc.) by applying to not only scalp of human but also pores and sebaceous glands distributed throughout the body, ), Acne, spots, freckles, spots, enlargement of pores, and the like.
상술한 목적을 달성하고자 하는 본 발명에 따른 여드름균 항균제는 가지(Solanum melongena L) 분말의 에탄올추출물을 포함한 것을 특징으로 한다.
The antimicrobial agent according to the present invention for achieving the above object is characterized by containing an ethanol extract of Solanum melongena L powder.
상기 가지 분말 에탄올추출물에는 루핀 종자 분말 또는 루핀 종자의 꼬투리 분말의 에탄올추출물을 더 혼합할 수 있다.
The ethanol extract of eggplant powder may further contain ethanol extract of lupine seed powder or lupine seed pod powder.
상기 가지 분말 에탄올추출물에는 오미자 분말의 에탄올추출물을 더 혼합할 수 있다.
The egg yolk ethanol extract may be further mixed with an ethanol extract of Omiza powder.
상기 에탄올추출에 사용되는 에탄올은 35℃~78℃로 가열된 고온 에탄올인 것을 특징으로 한다.
The ethanol used for the ethanol extraction is high-temperature ethanol heated to 35 ° C to 78 ° C.
상술한 목적을 달성하고자 하는 본 발명에 따른 화장품은 상기 추출물 혼합물을 여드름 방지 화장품에 1-20% 농도로 첨가하는 것을 특징으로 한다.
To achieve the above-mentioned object, the cosmetic product according to the present invention is characterized in that the extract mixture is added to the anti-acne cosmetic at a concentration of 1-20%.
상술한 조성을 갖는 본 발명에 따른 여드름균 항균제는 피부 자극과 부작용이 없으므로 사용상의 거부감이나 사용 후의 피부 발진이 없으며, 두피 뿐만아니라 몸 전체에 분포하는 모공이나 피지선에 서식하여 국소적인 병변 뿐 아니라 전신적인 피부병변을 야기하는 여드름균을 사멸하여 이로인한 천포창, 건선, 아토피성 피부염 등을 치료할 수 있을 뿐만 아니라, 여드름, 기미, 주근깨, 반점, 모공의 확대 등을 치료할 수 있으며, 두피에 적용할 경우 여드름균에 의한 모근 벽의 손상을 예방할 수 있고, 모근에서의 영양분 손실 원인 및 모공 확장 원인을 차단할 수 있게 되어 여드름 방지 및 여드름 부위 색소 침착을 감소할 수 있는 효과가 있다.
Since the antimicrobial agent of the present invention having the above composition has no irritation to the skin and side effects, there is no feeling of use, skin rash after use, and not only scalp but also follicles or sebaceous glands distributed throughout the body, It can treat pemphigus, psoriasis, atopic dermatitis and the like resulting from the killing of the acne causing the skin lesion, and it can treat acne, spots, freckles, spots and pores enlargement. When applied to the scalp, It is possible to prevent the damage of the hair follicle wall by the bacteria, to prevent the cause of the nutrient loss in the hair follicle and to prevent the growth of the pore, thereby reducing the occurrence of acne and the pigmentation of the acne area.
이하, 본 발명에 따른 여드름균 항균제 및 그것을 함유한 화장품을 상세히 설명한다.
Hereinafter, the acne antibacterial agent and the cosmetic containing it according to the present invention will be described in detail.
본 발명에 따른 여드름균 항균제는 가지 분말에 35℃-78°로 가열한 에탄올을 가하여 추출한 가지 분말의 에탄올추출물을 포함한다.
The acne antimicrobial agent according to the present invention comprises an ethanol extract of egg yolk powder extracted by adding ethanol heated at 35 ° C to 78 ° to egg yolk powder.
가지 분말 에탄올추출물에는 루핀 종자 분말 또는 루핀 종자의 꼬투리 분말의 에탄올추출물을 더 혼합할 수 있다. 가지 분말 에탄올추출물과 루핀 종자 분말 또는 루핀 종자의 에탄올추출물간의 혼합비율은 1:99중량% ~ 99:1중량%이다.
Egg powder ethanol extract can be further mixed with an ethanol extract of lupine seed powder or lupine seed pod powder. The mixing ratio between the ethanol extract of eggplant powder and the ethanol extract of lupine seed powder or lupine seed is 1:99 to 99: 1% by weight.
가지 분말 에탄올추출물에는 오미자 분말의 에탄올추출물을 더 혼합할 수 있다. 가지 분말 에탄올추출물과 오미자 분말 에탄올추출물간의 혼합비율은 1:99중량% ~ 99:1중량%이다.
The ethanol extract of eggplant powder can be further mixed with eggplant powder ethanol extract. The mixing ratio between the ethanol extract of eggplant powder and the ethanol extract of eggplant powder is 1:99 to 99: 1% by weight.
가지 분말 에탄올추출물에는 루핀 종자 분말 또는 루핀 종자의 꼬투리 분말의 에탄올추출물과 오미자 분말의 에탄올추출물을 더 혼합할 수 있다. 가지 분말 에탄올추출물과 오미자 분말 에탄올추출물간의 혼합비율은 1:99중량% ~ 99:1중량%이다. 이때의 혼합비율은 추출물전체 중량에 대하여 각각 1 ~ 99 중량% 혼합한다. 추출 용매로 사용하는 에탄올은 순도 95% 이상 에탄올이 바람직하다.
Eggplant powder ethanol extract can be further mixed with ethanol extract of lupine seed powder or lupine seed pod powder and ethanol extract of omija powder. The mixing ratio between the ethanol extract of eggplant powder and the ethanol extract of eggplant powder is 1:99 to 99: 1% by weight. In this case, the mixing ratio is 1 to 99% by weight based on the total weight of the extract. Ethanol used as an extraction solvent is preferably ethanol having a purity of 95% or more.
본 발명에 따른 가지(Solanum melongena L)는 가지는 1년생 초본식물로 줄기의 높이는 60∼100㎝ 내외로 타원형의 잎이 어긋나게 달리며, 6∼9월에 자주색의 통꽃이 핀다. 열매는 도란형(倒卵形: 계란을 거꾸로 세운 형태) 또는 원통형의 장과(奬果:살과 물이 많고, 속에 씨가 들어있는 과일)로 보통 검정색에 가까운 보라이지만 백색·황색도 있다.
The branch according to the present invention (Solanum melongena L) is a one-year-old herbaceous plant, the height of the stem is 60-100 cm in height, and the elliptical leaves are staggered and purple flowers bloom in June-September. Fruits are obovate (egg shaped) or cylindrical shaped fruit (奬果: fruit with lots of flesh and water and seeds in the inside). It is usually black, but it is white and yellow.
본 발명에 따른 여드름균 항균제의 제조 방법은 1) 가지를 건조한 후 분쇄하여 분말 상태로 마련하는 단계, 2) 가지 분말에 추출용매로서 95% 이상 에탄올을 1 : 3 ~ 1 : 10의 중량비로 가하여 35℃-78℃로 가열하면서 1-60일간 침지하여 추출용액을 얻는 단계를 포함한다. 본 발명에 따른 여드름균 항균제의 제조 방법은 가지 추출용액을 얻은 후, 3) 가지 추출용액을 여과하고 농축한 후 냉동 건조를 통해 분말화하는 농축분말화단계를 더 포함할 수 있다. 에탄올을 35℃-78℃로 가열하는 것은 가지로부터 루페올을 선택적으로 추출하기 위해서 필요하다.
The method for producing an acne antimicrobial agent according to the present invention comprises the steps of 1) drying and pulverizing branches to prepare a powder state, 2) adding 95% or more of ethanol as an extraction solvent in a weight ratio of 1: 3 to 1:10 And immersing it for 1 to 60 days while heating at 35 DEG C to 78 DEG C to obtain an extract solution. The method for producing an acne antimicrobial agent according to the present invention may further comprise a concentrated pulverization step of obtaining a branching extract solution, 3) filtering and concentrating the branching extract solution, and then lyophilizing the extract solution by freeze drying. Heating the ethanol to 35 ° C to 78 ° C is necessary to selectively extract lupeol from the branch.
본 발명에 따른 여드름균 항균제의 제조 방법은 1) 루핀 종자 또는 루핀 종자의 꼬투리를 건조한 후 분쇄하여 분말 상태로 마련하는 단계, 2) 루핀 종자 분말 또는 루핀 종자의 꼬투리 분말에 추출용매로서 95% 이상 에탄올을 1 : 3 ~ 1 : 10의 중량비로 가하여 35℃-78℃로 가열하면서 1-60일간 침지하여 루핀 종자 또는 루핀 종자의 꼬투리 추출용액을 얻는 단계를 포함한다. 본 발명에 따른 여드름균 항균제의 제조 방법은 루핀 종자 또는 루핀 종자의 꼬투리 추출용액을 얻은 후, 3) 추출용액을 여과하고 농축한 후 냉동 건조를 통해 분말화하는 농축분말화단계를 더 포함할 수 있다. 또한 본 발명에 따른 여드름균 항균제의 제조 방법은 4) 가지 추출용액 또는 그 농축분말과 루핀 종자 또는 루핀 종자의 꼬투리의 추출용액 또는 그 농축분말을 1:99중량%~99:1중량로 혼합하는 혼합단계를 더 포함한다. 에탄올을 35℃-78℃로 가열하는 것은 루핀 종자 또는 루핀 종자의 꼬투리로부터 루페올을 선택적으로 추출하기 위해서 필요하다.
The method for producing an acne antimicrobial agent according to the present invention comprises the steps of 1) drying and then pulverizing a pod of a lupine seed or a lupine seed to prepare a powder; 2) preparing a lupine seed powder or a lupine seed pod, Ethanol at a weight ratio of 1: 3 to 1:10 and immersing the solution in a temperature of 35 ° C to 78 ° C for 1-60 days to obtain a pod extract solution of lupine seed or lupine seed. The method for producing an acne antimicrobial agent according to the present invention may further comprise the step of obtaining a pod extract solution of lupine seed or lupine seed, 3) a concentrated pulverization step of filtering and concentrating the extract solution, followed by lyophilization through lyophilization have. The method for producing an antimicrobial agent according to the present invention comprises the steps of: 4) mixing a branched extract solution or an extract solution of the concentrated powder and a pod of a lupine seed or a lupine seed or a concentrated powder thereof at a weight ratio of 1:99 to 99: 1 Mixing step. Heating the ethanol to 35 < 0 > C to 78 < 0 > C is necessary to selectively extract lupeol from the poultice of lupine seed or lupine seed.
본 발명에 따른 여드름균 항균제의 제조 방법은 1) 오미자를 건조한 후 분쇄하여 분말 상태로 마련하는 단계, 2) 오미자의 꼬투리 분말에 추출용매로서 95% 이상 에탄올을 1 : 3 ~ 1 : 10 의 중량비로 가하여 35℃-78℃로 가열하면서 1-60일간 침지하여 오미자 추출용액을 얻는 단계를 포함한다. 본 발명에 따른 여드름균 항균제의 제조 방법은 오미자 추출용액을 얻은 후, 3) 추출용액을 여과하고 농축한 후 냉동 건조를 통해 분말화하는 농축분말화단계를 더 포함할 수 있다. 또한 본 발명에 따른 여드름균 항균제의 제조 방법은 4) 가지 추출용액 또는 그 농축분말과 오미자의 꼬투리의 추출용액 또는 그 농축분말을 1:99중량%~99:1중량로 혼합하는 혼합단계를 더 포함한다. 에탄올을 35℃-78℃로 가열하는 것은 오미자로부터 루페올을 선택적으로 추출하기 위해서 필요하다.
The method of producing an acne antimicrobial agent according to the present invention comprises the steps of 1) drying and pulverizing omiza to prepare a powder form, 2) adding 95% or more ethanol as an extraction solvent to the pod of Omiza at a weight ratio of 1: 3 to 1:10 And immersing it for 1 to 60 days while heating at 35 DEG C to 78 DEG C to obtain an extract of Omija. The method for producing an acne antimicrobial agent according to the present invention may further comprise a concentrated pulverization step of obtaining an omija extract solution, 3) filtering and concentrating the extract solution, followed by lyophilization by pulverization. Also, the method for producing an acne antimicrobial agent according to the present invention comprises 4) mixing a branch extract solution or a concentrated solution thereof with an extract solution of pomegranate or a concentrated powder thereof at a weight ratio of 1:99 to 99: 1 . Heating the ethanol to 35 ° C to 78 ° C is necessary to selectively extract Loupeol from Omija.
본 발명에 따른 여드름균 항균제의 제조 방법은 위의 각 단계에서 제조한 가지 추출용액과 루핀 종자 또는 루핀 종자의 꼬투리 추출용액과 오미자 추출용액을 전체질량에 대하여 각각 1중량%~99중량% 혼합하는 단계를 포함하거나, 각 단계에서 제조한 가지 농축분말과 루핀 종자 또는 루핀 종자의 꼬투리 농축분말과 오미자 농축분말 전체질량에 대하여 각각 1중량%~99중량% 혼합하는 단계를 포함할 수 있다.
The method for producing an acne antimicrobial agent according to the present invention comprises mixing the branch extract solution prepared in each of the above steps, the pod extract solution of lupine seed or lupine seed and the extract of Omija in an amount of 1 wt% to 99 wt% Or 1% by weight to 99% by weight of each of the bifurcated powder prepared in each step and the poddered powder of lupine seed or lupine seed and the total mass of the ozonized powder, respectively.
본 발명에 따른 화장품은 위 추출물 혼합물을 여드름 방지 화장품에 1-20% 농도로 첨가함으로써 얻어 진다.
The cosmetic product according to the present invention is obtained by adding the above extract mixture to an anti-acne cosmetic at a concentration of 1-20%.
이하에서는 본 발명에 따른 여드름균 항균제 및 화장품의 구체적인 실시예를 자세히 설명한다.
Hereinafter, concrete examples of the acne antibacterial agent and cosmetic product according to the present invention will be described in detail.
<실시 예 1>≪ Example 1 >
a) 가지, 꼬투리를 분리하지 않은 루핀 종자, 오미자의 95%에탄올 추출 - 가지, 꼬투리를 분리하지 않은 루핀 종자, 오미자를 분말형태로 2 ㎏씩 준비하였다. 가지에 95%에탄올을 8kg씩 가하여 45℃에서 10일간 침지한 후 채로 걸러 각각 6kg의 추출물 용액을 얻었다.
a) Lupine seeds which did not separate branches and pods, 95% ethanol extracts of omija - branches, lupine seeds which did not separate pods, and 2 ㎏ of powdered omija were prepared. 8 kg of 95% ethanol was added to each branch, and the mixture was immersed at 45 ° C for 10 days, and then 6 kg of each extract solution was obtained.
b) 혼합물 생성 : 위 방법으로 추출한 추출용액의 일부를 덜어, 순수 가지 추출용액, 가지 추출용액과 루핀 종자 추출용액의 1:1 혼합용액, 가지 추출용액과 오미자 추출용액의 1:1 혼합용액, 가지 추출용액과 루핀 종자 추출용액과 오미자 추출용액의 1:1:1의 혼합용액을 얻었다.
b) Formation of the mixture: A part of the extract solution extracted from the above method is taken out and mixed with a pure extract solution, a 1: 1 mixed solution of branch extract solution and lupine seed extract solution, a 1: 1 mixed solution of branch extract solution and Omija extract solution, A 1: 1: 1 mixed solution of branched extract, lupine seed extract and Omija extract was obtained.
전자현미경을 CCD카메라에 부착하여 컴퓨터에 연결한 후, 피검자의 코 옆 피지선에서 여드름을 짜듯 피지선을 압축하여 피지를 올라오게 하여 slide glass에 올려놓고 식물성 오일을 떨어뜨려 피지를 용해한 후 여드름균의 존재여부를 관찰하고 위 각각의 추출용액 또는 혼합용액을 50배 희석하여 검체에 떨어뜨리고 cover glass로 덮은 후 관찰하였다. 시간이 경과함에 따라 여드름균의 모양이 심하게 오그라들고, 움직임을 멈추며, 분해되어 아무 것도 보이지 않게 되는 데까지 약 4시간이 경과되는 것을 확인하였다. 위의 실험에서 본 발명에 따른 추출용액 또는 혼합용액을 50배로 희석하여 여드름균의 사멸시험을 한 것은 화장품이나 의약외품 등의 외용제로 사용가능한 농도에서 여드름균이 사멸하는 여부를 확인하기 위한 것이다.
After attaching the electron microscope to the CCD camera and connecting it to the computer, the sebaceous glands were compressed by pressing the sebaceous glands from the sebaceous glands next to the nose of the subject. The sebaceous glands were placed on a slide glass and the vegetable oil was dropped to dissolve the sebaceous glands. And each of the above extracts or mixed solutions was diluted 50 times, dropped on the specimens, covered with cover glass, and observed. It has been confirmed that about 4 hours have elapsed from the time when the appearance of acne bacterium is sharply shrunk, the movement is stopped, and it is disintegrated and nothing is seen. In the above experiment, the extinction test of the acne bacterium was conducted by diluting the extract solution or the mixed solution according to the present invention 50 times to confirm whether the acne bacterium was killed at a concentration that can be used as an external agent such as a cosmetic or a quasi-drug.
c) 실시 예 1 또는 실시 예 2에서 얻은 여드름균 항균제를 여드름 방지 화장품에 1-20중량% 농도로 첨가하여 여드름방지 기능을 갖는 화장품를 얻었다. 본 발명에 따른 여드름균 항균제는 크림, 엣센스, 스킨, 젤, 폰크린징, 팩, 토닉 등 일반적인으로 화장용 사용하는 제형에 약 1%-20%의 농도로 첨가하였다. 본 발명에 따른 여드름 항균제를 크림이나 폼클린징에 5%의 농도로 혼합하여, 피부에 바르고 거품을 낸 후 바로 씻지 않고 살균 성분이 여드름균에 작용하도록 20분 정도 경과 후에 씻는 것이 바람직하다고 확인되었다. 주로 지성피부를 동반하는 여드름에는 유분이 없는 팩 타입 또는 토닉타입의 제형을 적용하는 것이 바람직하였다.
c) The antimicrobial agent obtained in Example 1 or 2 was added to the anti-acne cosmetic at a concentration of 1-20% by weight to obtain a cosmetic having an anti-acne function. The acne antimicrobial agent according to the present invention is added to the formulation for cosmetic use such as cream, essence, skin, gel, pawn cleansing, pack, tonic and the like at a concentration of about 1% -20%. It was confirmed that it is preferable to mix the acne antimicrobial agent according to the present invention with cream or foam cleansing at a concentration of 5%, wash it after lapse of 20 minutes so that the sterilizing component acts on the acne bacterium without washing it immediately after applying foam on the skin. It is desirable to apply a pack or tonic type formulation that is free of oil to the acne that is primarily associated with oily skin.
본 발명에 따른 여드름균 항균제는 임상 시험 결과 다음과 같은 효과를 얻었다.
The clinical test results of the acne antimicrobial agent according to the present invention were as follows.
여드름 심한 사람들에게 연령에 구분 없이 무작위로 내복약 없이 본 발명에 따른 여드름균 항균제가 포함된 폰클렌징과 토닉을 같이 사용하도록 하고 경과를 관찰하였는데 대부분 사용과 동시에 염증이 줄기 시작하고 1-2개월 안에 깨끗하게 개선되었으며, 발진 등의 부작용은 전혀 나타나지 않았다. The patients who had severe acne were randomly assigned to one of the following treatments: age, sex, age, sex, age, sex, age, sex, And there were no side effects such as rashes.
Claims (5)
An antimicrobial agent for acne characterized by containing ethanol extract of eggplant powder (Solanum melongena L).
루핀 종자 분말 또는 루핀 종자의 꼬투리 분말의 에탄올추출물을 더 포함하는 여드름균 항균제.
The method according to claim 1,
An acne antimicrobial agent further comprising an ethanol extract of lupine seed powder or poultice seed powder.
오미자 분말의 에탄올추출물을 더 포함하는 여드름균 항균제를 함유한 여드름균 항균제.
The method according to claim 1,
An acne antimicrobial agent containing an acne antimicrobial agent further comprising an ethanol extract of an omia powder.
상기 에탄올추출에 사용되는 에탄올은 35℃~78℃로 가열된 고온 에탄올인 것을 특징으로 하는 여드름균 항균제.
4. The method according to any one of claims 1 to 3,
Wherein the ethanol used for the ethanol extraction is hot ethanol heated to 35 占 폚 to 78 占 폚.
A cosmetic comprising any one of the antimicrobial agents according to any one of claims 1 to 3.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160080139A KR102112382B1 (en) | 2016-06-27 | 2016-06-27 | Cosmetic composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160080139A KR102112382B1 (en) | 2016-06-27 | 2016-06-27 | Cosmetic composition |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20160085231A true KR20160085231A (en) | 2016-07-15 |
KR102112382B1 KR102112382B1 (en) | 2020-06-04 |
Family
ID=56506081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160080139A KR102112382B1 (en) | 2016-06-27 | 2016-06-27 | Cosmetic composition |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102112382B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102676799B1 (en) * | 2022-12-15 | 2024-06-20 | (주)티워크코리아 | External Composition Comprising Natural Complex Extract for Improving Skin |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102292763B1 (en) * | 2021-01-11 | 2021-08-25 | 방승섭 | Photocatalytic coating composition for sterilizatio device using LED lamp ultraviolet rays and sterilizatio device having member coated by the same |
KR102534775B1 (en) | 2021-05-07 | 2023-05-26 | 주식회사 클린힐 | Antibacterial composition comprising a natural extract mixture and a postbiotic mixture, a method for preparing an antibacterial composition for preparing an antibacterial composition comprising the natural extract mixture and a postbiotic mixture, and an antibacterial composition comprising the natural extract mixture and a postbiotic mixture Antimicrobial composition manufacturing apparatus for the preparation of the composition |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050152867A1 (en) * | 2004-01-12 | 2005-07-14 | Hwa Julie Y. | Skin treatment composition |
KR20120052991A (en) * | 2009-07-30 | 2012-05-24 | 라보라토이레즈 익스펜사이언스 | Cosmetic composition for the treatment of acne comprising a peptide extract of schizandra |
JP2012236815A (en) * | 2011-05-12 | 2012-12-06 | G & E Herbal Biotechnology Co Ltd | Treatment and/or prevention of inflammation and cutaneous photodamage and photoprotection of skin with water-soluble extract from plant of solanum genus |
-
2016
- 2016-06-27 KR KR1020160080139A patent/KR102112382B1/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050152867A1 (en) * | 2004-01-12 | 2005-07-14 | Hwa Julie Y. | Skin treatment composition |
KR20120052991A (en) * | 2009-07-30 | 2012-05-24 | 라보라토이레즈 익스펜사이언스 | Cosmetic composition for the treatment of acne comprising a peptide extract of schizandra |
JP2012236815A (en) * | 2011-05-12 | 2012-12-06 | G & E Herbal Biotechnology Co Ltd | Treatment and/or prevention of inflammation and cutaneous photodamage and photoprotection of skin with water-soluble extract from plant of solanum genus |
Non-Patent Citations (2)
Title |
---|
J. Investigative Dermatology,135권,1491-1500면(2015.03.05.) 1부.* * |
을지대학교 보건대학원 석사학위논문(박선희, 2013.02)* * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102676799B1 (en) * | 2022-12-15 | 2024-06-20 | (주)티워크코리아 | External Composition Comprising Natural Complex Extract for Improving Skin |
Also Published As
Publication number | Publication date |
---|---|
KR102112382B1 (en) | 2020-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kligman | An overview of acne | |
KR101267198B1 (en) | A method which manufactures shampoo for preventing loss of hair and promoting growth of hair | |
US20040170711A1 (en) | Medical effect of Jojoba oil in the treatment of anal diseases | |
KR20070079596A (en) | Functional cosmetic composition for the treatment of skin diseases | |
US4803069A (en) | Composition for the treatment of acne | |
CN107281048A (en) | One kind is without silicone oil herbal treatment shampoo and preparation method thereof | |
KR102354954B1 (en) | Fish Oil Topical Composition | |
TW201416071A (en) | Antiseptic, antiseborrheic and exfoliating composition to remove or prevent acne | |
KR20160085231A (en) | Propionibacterium Acnes Antimicrobial and Cosmetics Therewith | |
CN106265318A (en) | Prevention and the cosmetics dispelling skin sore acne and preparation method thereof | |
CN108056931A (en) | A kind of acne eliminating cream and preparation method thereof | |
KR101905836B1 (en) | Slightly acidic aronia natural soap and manufacturing method thereof | |
KR100418688B1 (en) | The growth inhibition of Propionibacterium acnes for the multiple extracts of herbal medicaments | |
KR100258612B1 (en) | Pack compositions for the prevention and treatment of acne | |
KR20120038699A (en) | A cosmetic composition containing bee venom | |
KR102293585B1 (en) | Wax-type cleanser | |
KR19990039050A (en) | Acne prevention and treatment containing wasp venom extract | |
KR20000065305A (en) | Skin care composition containing stabilized retinol, phytosphingosine, and Castaneae crenata extracts | |
KR101040011B1 (en) | Demodex fungicide | |
KR20040056079A (en) | Cosmetic composition for preventing and therapeutic for a pimple | |
KR100502069B1 (en) | Non-woven fabric pack impregnated with crude saponin of red ginseng for the improvement of acne | |
KR20140032516A (en) | Compositions for improving atopic dermatitis and acne, and manufacturing method thereof | |
KR100909729B1 (en) | Cosmetic composition for preventing and improving acne containing Namsil extract | |
KR20190132197A (en) | Cosmetic composition for use in the treatment and prevention of acne-prone skin | |
EA019383B1 (en) | Cosmetic preparation for body and face care (variants) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20160627 |
|
PG1501 | Laying open of application | ||
N231 | Notification of change of applicant | ||
PN2301 | Change of applicant |
Patent event date: 20170823 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
AMND | Amendment | ||
A201 | Request for examination | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20170907 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20160627 Comment text: Patent Application |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20181104 Patent event code: PE09021S01D |
|
AMND | Amendment | ||
E90F | Notification of reason for final refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Final Notice of Reason for Refusal Patent event date: 20190527 Patent event code: PE09021S02D |
|
AMND | Amendment | ||
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20191223 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20190527 Comment text: Final Notice of Reason for Refusal Patent event code: PE06011S02I Patent event date: 20181104 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
AMND | Amendment | ||
PX0901 | Re-examination |
Patent event code: PX09011S01I Patent event date: 20191223 Comment text: Decision to Refuse Application Patent event code: PX09012R01I Patent event date: 20190728 Comment text: Amendment to Specification, etc. Patent event code: PX09012R01I Patent event date: 20181228 Comment text: Amendment to Specification, etc. Patent event code: PX09012R01I Patent event date: 20170904 Comment text: Amendment to Specification, etc. |
|
PX0701 | Decision of registration after re-examination |
Patent event date: 20200212 Comment text: Decision to Grant Registration Patent event code: PX07013S01D Patent event date: 20200122 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I Patent event date: 20191223 Comment text: Decision to Refuse Application Patent event code: PX07011S01I Patent event date: 20190728 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I Patent event date: 20181228 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I Patent event date: 20170904 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I |
|
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20200512 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20200512 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20230601 Start annual number: 4 End annual number: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20240513 Start annual number: 5 End annual number: 5 |